Develops drugs for chemotherapy-induced neutropenia.
Jun 2026Revenue $0.00/yrExpenses $8.35M/yr
No trendCash runway ≈ 5 months from Jun 2026
Figures by year
When will BeyondSpring be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $0.00 and expenses $8.35M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $0.00 | $8.95M | −$8.95M |
| Dec 2024 | $0.00 | $8.75M | −$8.75M |
| Dec 2023 | $0.00 | $15.1M | −$15.1M |
| Dec 2022 | $1.35M | $38.6M | −$37.2M |
| Dec 2021 | $1.35M | $67.6M | −$66.2M |
| Dec 2020 | $180K | $64.4M | −$64.2M |
| Dec 2019 | $0.00 | $40.3M | −$40.3M |
| Dec 2018 | $0.00 | $57.5M | −$57.5M |
| Dec 2017 | $0.00 | $98.0M | −$98.0M |
| Dec 2016 | $0.00 | $12.4M | −$12.4M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.